Your source of breaking information about Dutasteride also known as Avodart, Avolve, GI198745, GG745 or Duagen.
dutasteride duagen avodart avolve 
  Dutasteride.org is an independent clearinghouse for information about Dutasteride and is not associated or affiliated with GlaxoSmithKline or the Glaxo Group Limited. Avolve, Avodart and Duagen are registered trademarks of Glaxo Group Limited.  


What is Dutasteride

The Latest News

Dutasteride Studies

Dutasteride Safety Profile

FDA Approval Documents

Dutasteride Results


If you are interested in getting more information via email about the availability of Avodart please enter your email address below

hair loss MPB Dutasteridedutastiride avolve duagen
 
Dutasteride Research Studies
 
Publication: Br J Clin Pharmacol 1999 Jan;47(1):53-8
Authors: Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO.
Institution: Clinical Pharmacology, GlaxoWellcome Research and Development, Middlesex, UK.
 
The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.
 

AIMS: To characterize the pharmacokinetics of the dual 5alpha-reductase inhibitor GI198745 (dutasteride) to allow for more accurate predictions of GI198745 concentrations after different dosing schedules.

METHODS: In this randomized, single-blind, parallel group study, 32 healthy male volunteers received single oral doses of GI198745 ranging from 0.01 to 40 mg. Data were analysed by nonlinear mixed effects modelling using NONMEM where both linear and nonlinear pharmacokinetic models were examined.

RESULTS: The time course of GI198745 serum concentrations indicated concentration dependent elimination, with the apparent half-life increasing with dose. Data were best described by a two-compartment model with first order absorption and parallel linear and nonlinear elimination pathways. Drug absorption was rapid, and was followed by a short distribution phase. A high volume of distribution (511 l) and a low linear clearance (0.58 l h(-1)) combined to give a half-life of up to 5 (1-7) weeks at high concentrations. As concentrations declined towards Km (0.96 ng ml(-1)), the proportion eliminated by the relatively rapid saturable elimination pathway, with a maximum clearance of 6.2 l h(-1), increased and the half-life reduced to about 3 days. The estimated inter individual variability for the linear clearance was high (CV = 70%).

CONCLUSIONS: G1198745 pharmacokinetics are well described by a pharmacokinetic model with parallel linear and nonlinear elimination. Simulations using this model show that at daily doses of 0.1 mg the steady state drug concentrations, and the rate at which these are achieved, are mainly influenced by the nonlinear pathway, while at daily doses above 1 mg they are almost entirely influenced by the linear pathway.

Publication Types:

  • Clinical Trial
  • Randomized Controlled Trial
 
lowers DHT and promotes hair regrowth
Glaxo sells Avodart also know as Dutasteride   Avolve Avodart  GI198745  Duagen
 
  Copyright © 2002 Interactive Marketing Group - All Rights Reserved - email: info@dutasteride.org